Trials / Withdrawn
WithdrawnNCT03515785
A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
A Postmarketing Observational Cohort Study to Evaluate Effectiveness and Safety of Ponatinib (Iclusig®) in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Incyte Biosciences International Sàrl · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness and safety of ponatinib (Iclusig®) in patients with BCR-ABL positive acute lymphoblastic leukemia (ALL) in standard clinical practice in Europe.
Conditions
Timeline
- Start date
- 2018-12-31
- Primary completion
- 2021-03-01
- Completion
- 2021-03-01
- First posted
- 2018-05-04
- Last updated
- 2018-12-14
Locations
10 sites across 3 countries: Czechia, France, Germany
Source: ClinicalTrials.gov record NCT03515785. Inclusion in this directory is not an endorsement.